

| | |
|---------------------------|---------|
| NUMBER OF COPIES RECEIVED | |
| DISTRIBUTION | |
| SANTA FE | |
| FILE | |
| U.S.S. | |
| LAND OFFICE | |
| TRANSPORTER | OIL GAS |
| PRODUCTION OFFICE | |
| OPERATOR | |

NEW MEXICO OIL CONSERVATION COMMISSION

Santa Fe, New Mexico

(Form C-104)
Revised 7/1/57

REQUEST FOR (OIL) - ~~(GAS)~~ ALLOWABLE

New Well
Recompletion

This form shall be submitted by the operator before an initial allowable will be assigned to any completed Oil or Gas well. Form C-104 is to be submitted in QUADRUPLICATE to the same District Office to which Form C-101 was sent. The allowable will be assigned effective 7:00 A.M. on date of completion or recompletion, provided this form is filed during calendar month of completion or recompletion. The completion date shall be that date in the case of an oil well when new oil is delivered into the stock tanks. Gas must be reported on 15.025 psia at 60° Fahrenheit.

Hobbs, New Mexico

11-9-64

(Place)

(Date)

WE ARE HEREBY REQUESTING AN ALLOWABLE FOR A WELL KNOWN AS:

Continental Oil Company State II-23, Well No. 5, in SW 1/4 SW 1/4,
(Company or Operator) (Lease)

M, Sec. 23, T. 10-S, R. 32-E, NMPM, Mescalero San Andres Pool
Unit Letter

Lea

County. Date Spudded 10-27-64

Date Drilling Completed 11-4-64

Please indicate location:

Elevation 4316 GR Total Depth 4270 PBTB

Top Oil/Gas ~~XXX~~ 4058 Name of Prod. Form. San Andres

PRODUCING INTERVAL - 4058-4164

Perforations 4065, 4070, 4074, 4079, 4092, 4100, 4112, 4126, 4139, 4150
& 4162 W/I JSPP Depth 4 1/2" @ 4270 Depth 4065
Open Hole Casing Shoe Tubing

OIL WELL TEST -

Natural Prod. Test: _____ bbls. oil, _____ bbls water in _____ hrs, _____ min. Choke Size _____

Test After Acid or Fracture Treatment (after recovery of volume of oil equal to volume of Choke load oil used): 134 bbls. oil, 9 bbls water in 19 hrs, 0 min. Size Swbd.

GAS WELL TEST -

Natural Prod. Test: _____ MCF/Day; Hours flowed _____ Choke Size _____

Method of Testing (pitot, back pressure, etc.): _____

Test After Acid or Fracture Treatment: _____ MCF/Day; Hours flowed _____

Choke Size _____ Method of Testing: _____

Acid or Fracture Treatment (Give amounts of materials used, such as acid, water, oil, and sand): 5000 gals 15% ISTNE acid

Casing Press. 150 Tubing Press. - Date first new oil run to tanks 11-8-64

Oil Transporter _____

Gas Transporter _____

Remarks: _____

I hereby certify that the information given above is true and complete to the best of my knowledge.

Approved: NOV 12 1964, 19____

Continental Oil Company

(Company or Operator)

G. C. Jamieson

By: _____ (Signature)

Title Assistant District Manager

Send Communications regarding well to:

Name Continental Oil Company

Address Box 460, Hobbs, N.M.

OIL CONSERVATION COMMISSION

By: _____

Title Engineer District 1

NMOCC (5) JM

CONTINENTAL OIL COMPANY

P.O. BOX 460
Hobbs, New Mexico
November 9, 1964

New Mexico Oil Conservation Commission
P. O. Box 2045
Hobbs, New Mexico

Gentlemen:

In compliance with New Mexico Oil Conservation Commission Rule 111, we are submitting below a list of deviation surveys taken on Continental Oil Company's State II-23 No. 5, located in Unit M, Section 23-10-32, Lea County, New Mexico:


| <u>Depth</u> | <u>Degree</u> |
|--------------|---------------|
| 100 | 1/4 |
| 445 | 1/4 |
| 770 | 1/2 |
| 1085 | 1/2 |
| 1300 | 3/4 |
| 1947 | 1/2 |
| 2385 | 3/4 |
| 2820 | 1 1/2 |
| 3320 | 1/2 |
| 3588 | 3/4 |
| 3940 | 1/2 |

Yours very truly,



G. C. JAMIESON
Assistant District Manager
Hobbs District

Subscribed and sworn to before me, a notary public in and for Lea County, New Mexico, this 10th day of November, 1964.



the 1990s, the number of people in the world who are under 15 years of age is expected to increase from 1.1 billion to 1.5 billion. The number of people aged 65 and over is expected to increase from 200 million to 400 million. The number of people aged 15 and over is expected to increase from 3.5 billion to 4.5 billion. The number of people aged 15 and over is expected to increase from 3.5 billion to 4.5 billion. The number of people aged 15 and over is expected to increase from 3.5 billion to 4.5 billion.

1. *Pharmaceuticals* (1997) 10, 1-12.
 2. *Pharmaceuticals* (1998) 11, 1-12.
 3. *Pharmaceuticals* (1999) 12, 1-12.
 4. *Pharmaceuticals* (2000) 13, 1-12.
 5. *Pharmaceuticals* (2001) 14, 1-12.
 6. *Pharmaceuticals* (2002) 15, 1-12.
 7. *Pharmaceuticals* (2003) 16, 1-12.
 8. *Pharmaceuticals* (2004) 17, 1-12.
 9. *Pharmaceuticals* (2005) 18, 1-12.
 10. *Pharmaceuticals* (2006) 19, 1-12.
 11. *Pharmaceuticals* (2007) 20, 1-12.
 12. *Pharmaceuticals* (2008) 21, 1-12.
 13. *Pharmaceuticals* (2009) 22, 1-12.
 14. *Pharmaceuticals* (2010) 23, 1-12.
 15. *Pharmaceuticals* (2011) 24, 1-12.
 16. *Pharmaceuticals* (2012) 25, 1-12.
 17. *Pharmaceuticals* (2013) 26, 1-12.
 18. *Pharmaceuticals* (2014) 27, 1-12.
 19. *Pharmaceuticals* (2015) 28, 1-12.
 20. *Pharmaceuticals* (2016) 29, 1-12.
 21. *Pharmaceuticals* (2017) 30, 1-12.
 22. *Pharmaceuticals* (2018) 31, 1-12.
 23. *Pharmaceuticals* (2019) 32, 1-12.
 24. *Pharmaceuticals* (2020) 33, 1-12.
 25. *Pharmaceuticals* (2021) 34, 1-12.
 26. *Pharmaceuticals* (2022) 35, 1-12.
 27. *Pharmaceuticals* (2023) 36, 1-12.
 28. *Pharmaceuticals* (2024) 37, 1-12.
 29. *Pharmaceuticals* (2025) 38, 1-12.
 30. *Pharmaceuticals* (2026) 39, 1-12.
 31. *Pharmaceuticals* (2027) 40, 1-12.
 32. *Pharmaceuticals* (2028) 41, 1-12.
 33. *Pharmaceuticals* (2029) 42, 1-12.
 34. *Pharmaceuticals* (2030) 43, 1-12.
 35. *Pharmaceuticals* (2031) 44, 1-12.
 36. *Pharmaceuticals* (2032) 45, 1-12.
 37. *Pharmaceuticals* (2033) 46, 1-12.
 38. *Pharmaceuticals* (2034) 47, 1-12.
 39. *Pharmaceuticals* (2035) 48, 1-12.
 40. *Pharmaceuticals* (2036) 49, 1-12.
 41. *Pharmaceuticals* (2037) 50, 1-12.
 42. *Pharmaceuticals* (2038) 51, 1-12.
 43. *Pharmaceuticals* (2039) 52, 1-12.
 44. *Pharmaceuticals* (2040) 53, 1-12.
 45. *Pharmaceuticals* (2041) 54, 1-12.
 46. *Pharmaceuticals* (2042) 55, 1-12.
 47. *Pharmaceuticals* (2043) 56, 1-12.
 48. *Pharmaceuticals* (2044) 57, 1-12.
 49. *Pharmaceuticals* (2045) 58, 1-12.
 50. *Pharmaceuticals* (2046) 59, 1-12.
 51. *Pharmaceuticals* (2047) 60, 1-12.
 52. *Pharmaceuticals* (2048) 61, 1-12.
 53. *Pharmaceuticals* (2049) 62, 1-12.
 54. *Pharmaceuticals* (2050) 63, 1-12.
 55. *Pharmaceuticals* (2051) 64, 1-12.
 56. *Pharmaceuticals* (2052) 65, 1-12.
 57. *Pharmaceuticals* (2053) 66, 1-12.
 58. *Pharmaceuticals* (2054) 67, 1-12.
 59. *Pharmaceuticals* (2055) 68, 1-12.
 60. *Pharmaceuticals* (2056) 69, 1-12.
 61. *Pharmaceuticals* (2057) 70, 1-12.
 62. *Pharmaceuticals* (2058) 71, 1-12.
 63. *Pharmaceuticals* (2059) 72, 1-12.
 64. *Pharmaceuticals* (2060) 73, 1-12.
 65. *Pharmaceuticals* (2061) 74, 1-12.
 66. *Pharmaceuticals* (2062) 75, 1-12.
 67. *Pharmaceuticals* (2063) 76, 1-12.
 68. *Pharmaceuticals* (2064) 77, 1-12.
 69. *Pharmaceuticals* (2065) 78, 1-12.
 70. *Pharmaceuticals* (2066) 79, 1-12.
 71. *Pharmaceuticals* (2067) 80, 1-12.
 72. *Pharmaceuticals* (2068) 81, 1-12.
 73. *Pharmaceuticals* (2069) 82, 1-12.
 74. *Pharmaceuticals* (2070) 83, 1-12.
 75. *Pharmaceuticals* (2071) 84, 1-12.
 76. *Pharmaceuticals* (2072) 85, 1-12.
 77. *Pharmaceuticals* (2073) 86, 1-12.
 78. *Pharmaceuticals* (2074) 87, 1-12.
 79. *Pharmaceuticals* (2075) 88, 1-12.
 80. *Pharmaceuticals* (2076) 89, 1-12.
 81. *Pharmaceuticals* (2077) 90, 1-12.
 82. *Pharmaceuticals* (2078) 91, 1-12.
 83. *Pharmaceuticals* (2079) 92, 1-12.
 84. *Pharmaceuticals* (2080) 93, 1-12.
 85. *Pharmaceuticals* (2081) 94, 1-12.
 86. *Pharmaceuticals* (2082) 95, 1-12.
 87. *Pharmaceuticals* (2083) 96, 1-12.
 88. *Pharmaceuticals* (2084) 97, 1-12.
 89. *Pharmaceuticals* (2085) 98, 1-12.
 90. *Pharmaceuticals* (2086) 99, 1-12.
 91. *Pharmaceuticals* (2087) 100, 1-12.
 92. *Pharmaceuticals* (2088) 101, 1-12.
 93. *Pharmaceuticals* (2089) 102, 1-12.
 94. *Pharmaceuticals* (2090) 103, 1-12.
 95. *Pharmaceuticals* (2091) 104, 1-12.
 96. *Pharmaceuticals* (2092) 105, 1-12.
 97. *Pharmaceuticals* (2093) 106, 1-12.
 98. *Pharmaceuticals* (2094) 107, 1-12.
 99. *Pharmaceuticals* (2095) 108, 1-12.
 100. *Pharmaceuticals* (2096) 109, 1-12.
 101. *Pharmaceuticals* (2097) 110, 1-12.
 102. *Pharmaceuticals* (2098) 111, 1-12.
 103. *Pharmaceuticals* (2099) 112, 1-12.
 104. *Pharmaceuticals* (2100) 113, 1-12.
 105. *Pharmaceuticals* (2101) 114, 1-12.
 106. *Pharmaceuticals* (2102) 115, 1-12.
 107. *Pharmaceuticals* (2103) 116, 1-12.
 108. *Pharmaceuticals* (2104) 117, 1-12.
 109. *Pharmaceuticals* (2105) 118, 1-12.
 110. *Pharmaceuticals* (2106) 119, 1-12.
 111. *Pharmaceuticals* (2107) 120, 1-12.
 112. *Pharmaceuticals* (2108) 121, 1-12.
 113. *Pharmaceuticals* (2109) 122, 1-12.
 114. *Pharmaceuticals* (2110) 123, 1-12.
 115. *Pharmaceuticals* (2111) 124, 1-12.
 116. *Pharmaceuticals* (2112) 125, 1-12.
 117. *Pharmaceuticals* (2113) 126, 1-12.
 118. *Pharmaceuticals* (2114) 127, 1-12.
 119. *Pharmaceuticals* (2115) 128, 1-12.
 120. <

9522 • J. Neurosci., September 24, 2008 • 28(39):9517–9524

[illegible]

the 1990s, the number of people in the United States who are 65 years of age or older is projected to increase from 20 million to 30 million, and the number of people 75 years of age or older is projected to increase from 10 million to 15 million (U.S. Census Bureau, 1996).